Similarly to DAPA-CKD, the EMPA-KIDNEY trial showed equally optimisitic results with Empagliflozin (an SGLT2-inhibitor) and included 6609 people with CKD of which many people living with Alport syndrome were included although Alport-specific data disappointingly remains unpublished [55]. This evidence concerns the gene SLC5A2 and Alport syndrome.